Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1

Conditions

Breast Neoplasms 134Carcinoma, Non-Small-Cell Lung 133Prostatic Neoplasms 87Lung Neoplasms 43Neoplasms 31Squamous Cell Carcinoma of Head and Neck 30Neoplasm Metastasis 29Stomach Neoplasms 26Head and Neck Neoplasms 24Esophageal Neoplasms 20Parkinson Disease 4, Autosomal Dominant Lewy Body 17Pancreatic Neoplasms 17Ovarian Neoplasms 16Urinary Bladder Neoplasms 13Sarcoma 12Adenocarcinoma of Lung 9Triple Negative Breast Neoplasms 8Fallopian Tube Neoplasms 8Carcinoma, Transitional Cell 8Carcinoma, Ovarian Epithelial 8Adenocarcinoma Of Esophagus 7Recurrence 6Inflammatory Breast Neoplasms 5Carcinoma, Squamous Cell 5Carcinoma 5Breast Neoplasms, Male 5Adenocarcinoma, Bronchiolo-Alveolar 5Laryngeal Neoplasms 4Esophageal Squamous Cell Carcinoma 4Advanced Solid Tumors 4

Interventions

pazopanib 1ixabepilone 1Gemcitabine 1Epothilones 1Docetaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Recurrent Uterine Corpus Sarcoma × Docetaxel × Clear all
NCT00114218 2019-01-08

Gemcitabine and Docetaxel in Treating Patients With Recurrent or Persistent Uterine Cancer

GOG Foundation

Phase 2 Completed
28 enrolled 7 charts
GynecologicSarcoma

Recurrent Uterine Corpus Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡